Gilead has announced it is to acquire nearly half of the cancer drug biotech Pionyr, with an exclusive option to acquire the rest of the company as the big pharma continues its expansion in
Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <
An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying sales could reach $7.7 billion in 2022.
The UK’s drugs regulator has said that there is enough evidence to support the use of Gilead’s COVID-19 drug remdesivir under its Early Access to Medicines Scheme (EAMS).